Analgesics

Analgesics

Global Analgesics Market to Reach US$72.8 Billion by 2030

The global market for Analgesics estimated at US$51.1 Billion in the year 2023, is expected to reach US$72.8 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Prescription Analgesics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in the OTC Analgesics segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$16.5 Billion While China is Forecast to Grow at 7.0% CAGR

The Analgesics market in the U.S. is estimated at US$16.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.8 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Analgesics Market - Key Trends & Drivers Summarized

Analgesics, commonly known as painkillers, are a diverse group of drugs used to relieve pain. They work by blocking pain signals in the brain or by interfering with the brain`s interpretation of these signals. There are several types of analgesics, each suited to different types and severities of pain. The most well-known categories include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, which reduce inflammation and are effective for mild to moderate pain. Opioids like morphine and oxycodone are stronger analgesics, often prescribed for severe pain but come with a risk of dependency and addiction. Another category is acetaminophen (paracetamol), which is widely used for mild to moderate pain relief and fever reduction, often included in over-the-counter medications.

The use of analgesics has evolved significantly over the years, driven by advances in medical research and an increasing understanding of pain mechanisms. New formulations and delivery methods, such as extended-release tablets and transdermal patches, have improved the efficacy and convenience of pain management. Additionally, the development of combination drugs that incorporate multiple analgesics into a single dose has enhanced pain relief outcomes by targeting different pain pathways simultaneously. However, the widespread use of analgesics, particularly opioids, has led to significant public health challenges, including the opioid crisis, characterized by high rates of addiction and overdose. This has prompted a shift towards finding safer, non-addictive pain relief options, such as the development of new NSAIDs with fewer gastrointestinal side effects and increased research into non-pharmacological therapies.

The growth in the analgesics market is driven by several factors. Advancements in drug delivery systems have made analgesics more effective and user-friendly, with innovations like patient-controlled analgesia pumps and wearable drug delivery devices gaining popularity. The rising prevalence of chronic diseases such as arthritis and cancer, which often require long-term pain management, has also fueled demand for analgesics. Additionally, an aging global population is contributing to increased consumption of these medications, as older adults are more likely to experience chronic pain conditions. Consumer behavior trends show a growing preference for over-the-counter analgesics for quick and accessible pain relief, further boosting market growth. Moreover, increased healthcare spending and greater access to medical care in developing regions are expanding the market`s reach. Pharmaceutical companies are also investing heavily in research and development to create new analgesics with better safety profiles and effectiveness, responding to the growing demand for safer alternatives to traditional painkillers. These factors collectively underscore the dynamic and expanding nature of the analgesics market.

Select Competitors (Total 146 Featured) -

• Bristol-Myers Squibb Company
• Bayer AG
• Biological E. Ltd.
• Anabolic Laboratories LLC
• BioDelivery Sciences International, Inc.
• Brawn Laboratories Ltd.
• Angelini Holding S.p.A.
• AFT Pharmaceuticals Limited
• APT Asia Pacific
• Church & Dwight (Australia) Pty Ltd.
• Alliance Design and Development Group, Inc.
• Active Releaf Wellness Inc.
• Abiogen Pharma S.p.A.
• B-New Limited
• Celgene Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.